Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy (NQF 0102)

eMeasure Name Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy eMeasure Id 79F42931-D09E-4775-967F-FB03753412D3
Version number 1 eMeasure Set Id 5EC265ED-E84F-4616-B6FC-A0885E98B8FF
Available Date No information Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward American Medical Association - Physician Consortium for Performance Improvement
Endorsed by National Quality Forum
Description Percentage of symptomatic patients aged 18 years and older with a diagnosis of COPD who were prescribed an inahled bronchodilator
Copyright
© 2010 American Medical Association. All Rights Reserved
Measure scoring Proportion
Measure type Process
Stratification
None
Risk Adjustment
None
Data Aggregation
Rationale
Inhaled bronchodilator therapy is effective in treating and managing the symptoms of COPD, particularly, for those patients with moderate to very severe COPD, and improving a patient's quality of life.
Clinical Recommendation Statement
Short-acting bronchodilators can increase exercise tolerance acutely in COPD (ATS and ERS). Bronchodilator medications are central to the symptomatic management of COPD (NHLBI/WHO). A combination of short-acting β2-agonist and an anticholinergic produces greater and more sustained improvements in FEV1 than either alone and does not produce evidence of tachphylaxis over 90 days of treatment (NHLBI/WHO). In patients with Stage II: Moderate COPD to Stage IV: Very Sever COPD whose symptoms are not adequately controlled with as-needed short-acting bronchodilators, adding regular treatment with a long-acting inhaled bronchodilator is recommended (NHLBI/WHO). Regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators, but more expensive (NHLBI/WHO).
Improvement notation
Higher score indicates better quality
Measurement duration
12 month(s)
Reference
American Thoracic Society (ATS), European Respiratory Society (ERS). Standards for the Diagnosis and Management of COPD. Available at: http://www.thoracic.org/copd/. Accessed September 2004.
Reference
National Heart, Lung, and Blood Institute/World Health Organization. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Updated 2004. Available at http://www.goldcopd.com. Accessed September 2004.
Definition
Prescribed:  Includes patients who are currently receiving medication(s) that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter.
Definition
Initial Patient Population(s): Patient Age:  Patients aged 18 years and older at the beginning of the measurement period. Diagnosis Active: Patient has a documented diagnosis of chronic obstructive pulmonary disease (COPD).

Encounter:  At least 2 face-to-face office visits with physician, physicians' assistant, or nurse practitioner occurring during the measurement time period.
Definition
Denominator(s): All patients aged 18 years and older with a diagnosis of COPD who have a forced expiratory volume at 1 second (FEV1)/forced vital capacity (FVC) ratio <70% and have symptoms.
Definition
Denominator Exclusion(s): N/A
Definition
Numerator(s): All symptomatic patients who were prescribed an inhaled bronchodilator.
Definition
Denominator Exception(s): Documentation of medical reason(s) for not prescribing an inhaled bronchodilator (eg, clinical contraindication, drug allergy, drug interaction, drug intolerance, other medical reason(s)). Documentation of patient reason(s) for not prescribing an inhaled bronchodilator (eg, patient declined). Documentation of a system reason(s) for not prescribing an inhaled bronchodilator.
Guidance
Supplemental Data Elements
Report "Patient Characteristic: Gender" using "Gender HL7 Value Set (2.16.840.1.113883.1.11.1)"; Report "Patient Characteristic: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"; Report "Patient Characteristic: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"; Report "Patient Characteristic: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)".

Table of Contents


Population criteria

Data criteria (QDM Data Elements)

Supplemental Data Elements




Measure set CLINICAL QUALITY MEASURE SET 2011-2012